Combined Platelet and Erythrocyte Salvage: Evaluation of a New Filtration-based Autotransfusion Device

Archive ouverte

Mansour, Alexandre | Decouture, Benoit | Roussel, Mikaël | Lefevre, Charles | Skreko, Lucie | Picard, Veronique | Ouattara, Alexandre | Bachelot-Loza, Christilla | Gaussem, Pascale | Nesseler, Nicolas | Gouin-Thibault, Isabelle

Edité par CCSD ; Lippincott, Williams & Wilkins -

International audience. Background: The SAME device (i-SEP, France) is an innovative filtration-based autotransfusion device able to salvage and wash both red blood cells and platelets. This study evaluated the device performances using human whole blood with the hypothesis that the device will be able to salvage platelets while achieving a erythrocyte yield of 80% and removal ratios of 90% for heparin and 80% for major plasma proteins without inducing signification activation of salvaged cells. Methods: Thirty healthy human whole blood units (median volume, 478 ml) were diluted, heparinized, and processed by the device in two consecutive treatment cycles. Samples from the collection reservoir and the concentrated blood were analyzed. Complete blood count was performed to measure blood cell recovery rates. Flow cytometry evaluated the activation state and function of platelets and leukocytes. Heparin and plasma proteins were measured to assess washing performance. Results: The global erythrocyte yield was 88.1% (84.1 to 91.1%; median [25th to 75th]) with posttreatment hematocrits of 48.9% (44.8 to 51.4%) and 51.4% (48.4 to 53.2%) for the first and second cycles, respectively. Ektacytometry did not show evidence of erythrocyte alteration. Platelet recovery was 36.8% (26.3 to 43.4%), with posttreatment counts of 88 x 10(9)/l (73 to 101 x 10(9)/l) and 115 x 10(9)/l (95 to 135 x 10(9)/l) for the first and second cycles, respectively. Recovered platelets showed a low basal P-selectin expression at 10.8% (8.1 to 15.2%) and a strong response to thrombin-activating peptide. Leukocyte yield was 93.0% (90.1 to 95.7%) with no activation or cell death. Global removal ratios were 98.3% (97.8 to 98.9%), 98.2% (96.9 to 98.8%), and 88.3% (86.6 to 90.7%) for heparin, albumin, and fibrinogen, respectively. The processing times were 4.4 min (4.2 to 4.6 min) and 4.4 min (4.2 to 4.7 min) for the first and second cycles, respectively. Conclusions: This study demonstrated the performance of the SAME device. Platelets and red blood cells were salvaged without significant impact on cell integrity and function. In the meantime, leukocytes were not activated, and the washing quality of the device prevented reinfusion of high concentrations of heparin and plasma proteins.

Consulter en ligne

Suggestions

Du même auteur

Platelet Functions During Extracorporeal Membrane Oxygenation. Platelet-Leukocyte Aggregates Analyzed by Flow Cytometry as a Promising Tool to Monitor Platelet Activation

Archive ouverte | Mansour, Alexandre | CCSD

International audience. Extracorporeal membrane oxygenation (ECMO) is an extracorporeal circulation used to manage patients with severe circulatory or respiratory failure. It is associated with both high bleeding an...

P2Y Inhibition beyond Thrombosis Effects on Inflammation

Archive ouverte | Mansour, Alexandre | CCSD

International audience. The P2Y receptor is a key player in platelet activation and a major target for antithrombotic drugs. The beneficial effects of P2Y receptor antagonists might, however, not be restricted to th...

Evaluation of commonly used tests to measure the effect of single-dose aspirin on mouse hemostasis

Archive ouverte | Decouture, Benoit | CCSD

PG and CBL share equal senior authorship.. International audience. Discrepancies in preclinical studies of aspirin (ASA) antiplatelet activity in mouse models of bleeding and arterial thrombosis led us to evaluate c...

Chargement des enrichissements...